Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) FCF Margin (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed FCF Margin for 5 consecutive years, with 23.36% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin rose 2007.0% year-over-year to 23.36%, compared with a TTM value of 9.81% through Dec 2025, up 2802.0%, and an annual FY2025 reading of 9.81%, up 2802.0% over the prior year.
  • FCF Margin was 23.36% for Q4 2025 at Xeris Biopharma Holdings, down from 24.78% in the prior quarter.
  • Across five years, FCF Margin topped out at 24.78% in Q3 2025 and bottomed at 292.32% in Q1 2021.
  • Average FCF Margin over 5 years is 72.24%, with a median of 42.4% recorded in 2023.
  • The sharpest move saw FCF Margin surged 14471bps in 2022, then plummeted -1354bps in 2024.
  • Year by year, FCF Margin stood at 134.06% in 2021, then skyrocketed by 64bps to 48.63% in 2022, then skyrocketed by 135bps to 16.83% in 2023, then crashed by -80bps to 3.29% in 2024, then soared by 611bps to 23.36% in 2025.
  • Business Quant data shows FCF Margin for XERS at 23.36% in Q4 2025, 24.78% in Q3 2025, and 0.25% in Q2 2025.